European Cancer Congress | Conference

Patients With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10th 2021

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29th 2017

Pembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.

Dr. Raffit Hassan on Avelumab in Unresectable Mesothelioma

October 12th 2015

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Dr. Poortmans on Impact of Multidisciplinary Approach on Side Effect Management

October 7th 2015

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.

Dr. Lambertini on Preserving Ovarian Function and Fertility During Chemotherapy Treatment

October 6th 2015

Matteo Lambertini, MD, Department of Medical Oncology, U.O. Oncologia Medica A, Hospital San Martino, Genova, Italy, discusses the use of luteinizing hormone-releasing hormone agonists (LHRHa) during chemotherapy to preserve ovarian function and fertility in patients with breast cancer.

Dr. Andrea Apolo on Treatment Challenges in Metastatic Bladder Cancer

October 2nd 2015

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses treatment challenges for patients with refractory, metastatic urothelial carcinoma.

Dr. Johan Vansteenkiste on Atezolizumab in NSCLC

October 1st 2015

Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non–small cell lung cancer (NSCLC).

Dr. Pietanza on Rova-T for Small Cell Lung Cancer

September 30th 2015

Catherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses novel targeted therapy rovalpituzumab tesirine (Rova-T), which showed activity in relapsed and refractory small cell lung cancer (SCLC) in a recent phase I study.

Telotristat Etiprate Curbs Carcinoid Syndrome in Neuroendocrine Tumors

September 30th 2015

Treatment with telotristat etiprate reduced the average number of daily bowel movements by up to 35% for patients with carcinoid syndrome that was not adequately controlled by a somatostatin analog.

Erlotinib/Bevacizumab Effective in EGFR T790M-Mutant NSCLC

September 29th 2015

Treatment with the frontline combination of erlotinib and bevacizumab was highly effective in patients with advanced non–small cell lung cancer who harbored an EGFR T790M mutation.

Longer Follow-up Confirms Nivolumab OS Benefit in Nonsquamous NSCLC

September 28th 2015

Treatment with nivolumab reduced the risk of death by 28% compared with docetaxel for patients with previously treated nonsquamous non–small cell lung cancer.

Novel Antibody-Drug Conjugate Shows Promise in SCLC

September 28th 2015

The antibody-drug conjugate rovalpituzumab tesirine demonstrated activity across a range of patients with relapsed and refractory small-cell lung cancer.

Updated Pembrolizumab Lung Cancer Data Presented as FDA Decision Nears

September 28th 2015

Data from the pivotal KEYNOTE-001 trial showing pembrolizumab's efficacy in pretreated non–small cell lung cancer (NSCLC) were presented at the 2015 European Cancer Congress, just days before the FDA is scheduled to make its approval decision on the PD-1 inhibitor in this setting.

Fosaprepitant Improves Emesis Control in Women Receiving Chemoradiotherapy for Cervical Cancer

September 28th 2015

Adding fosaprepitant (Emend) to an antiemetic regimen significantly improved emesis control versus standard care in women receiving radiotherapy and cisplatin for cervical cancer.

Dr. Andrea Apolo on Avelumab in Metastatic Bladder Cancer

September 28th 2015

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses a phase 1b trial investigating avelumab, an anti-PD-L1 antibody, in patients with refractory, metastatic urothelial carcinomas.

Dr. Dirk Arnold Discusses the CONSIGN Study

September 28th 2015

Dirk Arnold, MD, Director Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, Arnold Discusses the CONSIGN Study.

Dabrafenib/Trametinib Combo Improves OS Versus Vemurafenib in Advanced Melanoma

September 27th 2015

The combination of dabrafenib plus trametinib improved overall survival by 7.6 months compared with single-agent vemurafenib in patients with unresectable or metastatic BRAFV600E/K-mutant melanoma.

T-VEC/Pembrolizumab Combination Demonstrates Safety in Melanoma

September 27th 2015

The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.

Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma

September 27th 2015

Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.

Two Pivotal Studies Show Efficacy of Atezolizumab in PD-L1-Positive NSCLC

September 27th 2015

Inhibition of PD-L1 with atezolizumab demonstrated significant clinical efficacy as monotherapy in patients with advanced non-small cell lung cancer.